ArticleBJUI compass2025
Long-term assessment of adverse cardiovascular events in men receiving intermittent androgen deprivation therapy following radical prostatectomy.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the relationship of intermittent adverse cardiovascular events (ACE) in men undergoing androgen deprivation therapy (ADT) post radical prostatectomy (RP), since ACE are severe complications associated with ADT following a biochemical recurrence (BCR) post-RP for the treatment of prostate cancer (PC). Patients and Methods: Retrospective review of prospectively collected data of patients who underwent robot-assisted radical prostatectomy (RARP) with a BCR (n = 407). A total of 308 men with adequate follow-up data included for analysis. A total of 189/308 men in the "treatment group" (TG) were managed with ADT. The comparator group consisted of 119/308 men with no treatment (NT). Regression and Kaplan Meier (KM) analyses were performed to assess predictors of ACE. Results: At baseline, patients in the treatment group had higher risk characteristics for PC (preoperative PSA, pathological stage and Gleason grade). Univariate analysis of ACE showed significant predators were age, Charlson comorbidity index (CCI), body mass index (BMI), treatment status and smoking status. In multivariate analysis, treatment status was trending towards significance (p = 0.10) with CCI (p < 0.001) and BMI (p = 0.003) being significant predictors of ACE. In 15-year KM, we observed a significant increase in ACEs (TG 54.4% and NT 41.8%, p = 0.02). Limitations include retrospective design and limited analysis of NT, TG or ADT effects on cardiovascular mortality. Conclusion: ADT, in our experience, is associated with an increased risk of ACE. We also noted the importance of CCI and BMI as a prognosticating tool for ACE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.